IL131386A0 - Method for the detection and localization of malignant human tumours - Google Patents

Method for the detection and localization of malignant human tumours

Info

Publication number
IL131386A0
IL131386A0 IL13138698A IL13138698A IL131386A0 IL 131386 A0 IL131386 A0 IL 131386A0 IL 13138698 A IL13138698 A IL 13138698A IL 13138698 A IL13138698 A IL 13138698A IL 131386 A0 IL131386 A0 IL 131386A0
Authority
IL
Israel
Prior art keywords
detection
composition
relates
neurotensin
malignant tumors
Prior art date
Application number
IL13138698A
Other languages
English (en)
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Publication of IL131386A0 publication Critical patent/IL131386A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/085Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
IL13138698A 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours IL131386A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200297 1997-02-03
PCT/US1998/001964 WO1998033531A1 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Publications (1)

Publication Number Publication Date
IL131386A0 true IL131386A0 (en) 2001-01-28

Family

ID=26146106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13138698A IL131386A0 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Country Status (11)

Country Link
US (2) US6312661B1 (de)
EP (1) EP0968001B1 (de)
JP (1) JP2001511152A (de)
AT (1) ATE253381T1 (de)
AU (1) AU728712C (de)
CA (1) CA2279530C (de)
DE (1) DE69819478T2 (de)
HU (1) HUP0001316A3 (de)
IL (1) IL131386A0 (de)
NO (1) NO993846L (de)
WO (1) WO1998033531A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3340699B2 (ja) * 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
US7232559B1 (en) 1999-06-04 2007-06-19 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
AU2119101A (en) * 1999-10-22 2001-05-08 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
US7630907B2 (en) * 2001-10-30 2009-12-08 Biodose, Llc Algorithm and program for the handling and administration of radioactive pharmaceuticals
US8175890B2 (en) * 2001-10-30 2012-05-08 Biodose, Llc Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20040039241A1 (en) * 2002-05-29 2004-02-26 Biodose Llc Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals
WO2004009614A2 (en) * 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
GR1004637B (el) * 2003-04-04 2004-07-23 Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουᐏ@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
US7507547B2 (en) * 2004-09-09 2009-03-24 University Of Massachusetts Screening assays for antioxidants and antiproliferative compounds
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
US8586043B2 (en) 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
US9809624B2 (en) * 2009-07-16 2017-11-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
EP2740726A1 (de) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin-Rezeptorligande
EP2954933A1 (de) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Konjugat mit einem Neurotensinrezptorligand
WO2015188934A1 (en) 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954934A1 (de) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Konjugat aus einem Neurotensinrezeptorliganden und Verwendung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
EP0636032A1 (de) * 1992-03-25 1995-02-01 Mallinckrodt Medical, Inc. Methode zur Feststellung und Lokalisierung von Tumorgeweben während einerOperation
CA2086453A1 (en) * 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0752873A4 (de) * 1994-02-18 2002-05-15 Mallinckrodt Inc Markierte peptidverbindungen
FR2720066B1 (fr) * 1994-05-20 1996-06-28 Rhone Poulenc Rorer Sa Peptides antagonistes de la neurotensine.
FR2722193B1 (fr) * 1994-07-08 1996-10-04 Sanofi Sa Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant
WO1996023527A1 (en) * 1995-02-03 1996-08-08 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours

Also Published As

Publication number Publication date
JP2001511152A (ja) 2001-08-07
NO993846L (no) 1999-09-09
AU6262298A (en) 1998-08-25
US6312661B1 (en) 2001-11-06
US20020155064A1 (en) 2002-10-24
HUP0001316A2 (hu) 2000-09-28
AU728712C (en) 2001-07-19
CA2279530A1 (en) 1998-08-06
AU728712B2 (en) 2001-01-18
CA2279530C (en) 2009-04-28
DE69819478T2 (de) 2004-09-02
EP0968001B1 (de) 2003-11-05
WO1998033531A1 (en) 1998-08-06
HUP0001316A3 (en) 2001-10-29
NO993846D0 (no) 1999-08-10
ATE253381T1 (de) 2003-11-15
EP0968001A1 (de) 2000-01-05
DE69819478D1 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
IL131386A0 (en) Method for the detection and localization of malignant human tumours
Raderer et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
US11547767B2 (en) 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen
EP3766893B1 (de) 177lu-dota-hynic-ipsma als therapeutisches radiopharmakon gegen das prostataspezifische membranantigen
Tjuvajev et al. Iododeoxyuridine uptake and retention as a measure of tumor growth
US20130330274A1 (en) Compositions and methods for detecting and treating cancer
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
Bonnet‐Duquennoy et al. Targeted radionuclide therapy of melanoma: anti‐tumoural efficacy studies of a new 131I labelled potential agent
Liu et al. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor
N Eberle et al. Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions
O'Byrne et al. Scintigraphic imaging of small-cell lung cancer with [111In] pentetreotide, a radiolabelled somatostatin analogue
Nagy et al. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers
US9180214B1 (en) Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
Guo et al. A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
Yang et al. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent
Merlo et al. Biodistribution of 111In‐labelled SCN‐bz‐DTPA‐BC‐2 MAb following loco‐regional injection into glioblastomas
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
Wygoda et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors
Nock et al. Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1–preclinical and first clinical results
Liu et al. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone
Raderer et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results
Arista et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas
JP2002516882A5 (de)
JP2022517662A (ja) 腫瘍細胞外マトリックスにおける腫瘍性タンパク質に特異的なペプチドpet/spectプローブ